BiOrion is a Dutch clinical stage biopharmaceutical drug discovery company engaged in developing targeted therapeutics and companion imaging diagnostics for fibrotic diseases. These diseases include cardiac fibrosis and hepatic fibrosis, and fibrosis-associated cancers such as colorectal cancer. BiOrion's platform and drug development engine is based on proprietary PDGF-ß-receptor binding bicyclic peptides that act as targeting vehicles for diagnostic PET radionuclides and (existing) anti-fibrotic therapeutics.
Fibrotic tissue is characterized by abundant myofibroblast-specific overexpression of the PDGF-ß-receptor. This over-expressed receptor allows myofibroblast-specific targeting and delivery of antifibrotic drugs, thereby leaving healthy tissues unaffected. After binding of BiOrion’s peptide-conjugate to the receptor, the complex is internalized and accumulated rapidly and, dependent on the payload, can exert its intracellular effect.
BiOrion has two active development programs. In the diagnostic imaging program BOT501 the bicyclic peptide is conjugated to a 18F-PET radionuclide. BOT501 is developed to identifying and stratifying patients with cardiac fibrosis, hepatic fibrosis or colorectal cancer as well as following up disease-specific targeted therapy. In the therapeutic program BOT191 the bicyclic peptide is conjugated to the signaling domain of interferon gamma. BOT191 is developed for targeted anti-fibrotic therapy of patients suffering from cardiac fibrosis, hepatic fibrosis or colorectal cancer.